source
- J&J/Protagonist’s oral Icotyde shows Phase 3 benefit in psoriatic arthritis but trails AbbVie’s SkyriziA Phase 3 study of Johnson & Johnson and Protagonist Therapeutics’ oral IL‑23 receptor antagonist Icotyde met its primary endpoint, demonstrating improvement in psoriatic arthritis symptoms. In th…
- Lilly's oral GLP-1 pill Foundayo reduces sleep apnea events in late-stage trialsIn two late-stage trials, Eli Lilly’s oral GLP‑1 pill Foundayo lowered the apnea‑hypopnea index by an average of 17.8 events per hour, compared with a 4.5‑event reduction for patients on placebo.…